Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10998-3
TRI-611 induces the degradation of ALK fusion proteins via a previously undescribed CRBN recruitment motif, and its preclinical anti-tumour activity highlights TRI-611 as a potential new way of treating ALK-positive non-small-cell lung cancer.TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10998-3TRI-611 induces the degradation of ALK fusion proteins via a previously undescribed CRBN recruitment motif, and its preclinical anti-tumour activity highlights …